MoonLake Immunotherapeutics (MLTX)

NASDAQ: MLTX · Real-Time Price · USD

48.19

+0.14 (0.29%)

Oct 29, 2024, 4:00 PM EDT - Market closed

MLTX Employees

MoonLake Immunotherapeutics had 50 employees as of December 31, 2023. The number of employees increased by 30 or 150.00% compared to the previous year.

Employees

50

Change (1Y)

30

Growth (1Y)

150.00%

Revenue / Employee

n/a

Profits / Employee

-$1,096,076

Market Cap

3.03B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	50	30	150.00%
Dec 31, 2022	20	-	-

Related Stocks

Company Name	Employees
Bausch Health Companies	20,270
Amedisys	19,000
Neogen	2,917
LivaNova	2,900
PTC Therapeutics	1,055
Rhythm Pharmaceuticals	226
Scholar Rock Holding	150
Dyne Therapeutics	141

Employee Rankings

MLTX News

7 weeks ago - MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 - GlobeNewsWire
3 months ago - MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward - Seeking Alpha
5 months ago - MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa - GlobeNewsWire
6 months ago - MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion - Seeking Alpha
6 months ago - MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
7 months ago - MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions - GlobeNewsWire
7 months ago - MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions - Business Wire
8 months ago - MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day - GlobeNewsWire